Adult recipients of autologous or allogeneic hematopoietic-cell transplants (HCT) are at high risk for respiratory syncytial virus (RSV) infection and associated morbidity and mortality. Up to 17% of HCT recipients may develop an RSV infection \[[@CIT0001]\], of whom 17% to 84% progress from an upper respiratory tract infection (URTI) to a lower respiratory tract infection (LRTI) \[[@CIT0002], [@CIT0003], [@CIT0005], [@CIT0007]\]. Progression to a LRTI often requires hospitalization, during which oxygen supplementation and intensive care may be required; RSV LRTIs are associated with increased mortality rates, ranging from 6% to 35% \[[@CIT0002], [@CIT0004], [@CIT0008], [@CIT0009], [@CIT0015]\]. Survivors of a respiratory viral infection after HCT may have a long-term airflow decline \[[@CIT0015], [@CIT0021]\].

Currently, there are no effective vaccines or approved antiviral agents for RSV infection in HCT recipients. Aerosolized ribavirin (Virazole) is approved for the treatment of RSV infections in young children but is not used in general pediatric practice because of efficacy and tolerability concerns and the complexity of the required specialized aerosol delivery system \[[@CIT0022]\]. A randomized, placebo-controlled trial of aerosolized ribavirin attempted in HCT recipients recruited only 14 subjects in 5 years due to slow accrual \[[@CIT0025]\]. Epidemiologic studies and a single-center, retrospective analysis suggest that ribavirin-based therapy has some efficacy for preventing RSV-associated morbidity or mortality in high-risk HCT recipients \[[@CIT0006], [@CIT0014], [@CIT0018]\]. However, these results are from uncontrolled, retrospective studies and the ribavirin benefit remains unconfirmed. Thus, there remains a significant, unmet medical need for safe, convenient, and effective treatments for RSV infection.

Presatovir (formerly GS-5806) is an oral RSV fusion inhibitor with potent and selective anti-RSV activity in vitro and a terminal half-life of \~34 hours \[[@CIT0026]\]. When tested in a human challenge study of healthy volunteers, presatovir reduced the RSV viral load and the severity of clinical disease \[[@CIT0026]\]. In the current study, we evaluated presatovir's safety, tolerability, and efficacy among HCT recipients with RSV URTIs.

PATIENTS AND METHODS {#s1}
====================

Patients and Study Design {#s2}
-------------------------

This Phase II, randomized, double-blind, placebo-controlled, 2-group, parallel study recruited allogeneic or autologous HCT recipients with positive local RSV test results who were 18 to 75 years of age from 43 centers in 9 countries (Supplementary Appendix). Patients with new or worsening respiratory symptoms for ≤7 days, who had been diagnosed with an RSV infection of the upper respiratory tract for ≤6 days, and who were without new abnormalities on a chest X-ray obtained \<48 hours from the start of study treatment were eligible to participate. Patients with a specified, documented respiratory virus coinfection within 7 days from the start of study treatment or with another significant respiratory or systemic infection were excluded. The full eligibility criteria are provided in the [Supplementary Methods](#sup1){ref-type="supplementary-material"}.

This study followed International Conference on Harmonization requirements and the principles of the Declaration of Helsinki and was approved by local ethics committees. Written informed consent was obtained from patients or their legally responsible representatives. The protocol amendments and Data Monitoring Committee activities are described in the [Supplementary Methods](#sup1){ref-type="supplementary-material"}. The trial was registered at ClinicalTrials.gov (NCT02254408) and EudraCT (2014-002474-36) before enrollment began.

Randomization and Masking {#s3}
-------------------------

Patients were randomly assigned (1:1) to receive presatovir or a placebo, were stratified centrally by lymphopenia (lymphocyte count \<200 cells/mm^3^ within 6 days of screening), and were prescribed the use of ribavirin by any route of administration at randomization. The study treatment assignments were provided by an interactive web response system (Bracket Global, Wayne, PA, USA). Patients, all study staff, and the study sponsor were blinded to study treatment. Allocation was concealed by the use of presatovir and placebo tablets that were identical in appearance.

Procedures {#s4}
----------

The patients received presatovir at 200 mg (4 × 50 mg tablets) or a placebo orally or by a nasogastric tube during study visits on Days 1, 5, 9, 13, and 17 (±24 hours), and were followed through study Day 28. Based on human pharmacokinetic and pharmacodynamic studies \[[@CIT0026]\], this regimen was predicted to provide plasma concentrations \>4-fold over requirements to inhibit the replication of \>95% of tested RSV isolates. Patients with detectable RSV by reverse transcription quantitative polymerase chain reaction (RT-qPCR) on Day 22 could participate in an optional extended, weekly follow-up through Day 56. A detailed schedule of the study assessments and procedures is provided in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

Plasma pharmacokinetic methods are described in the [Supplementary Methods](#sup1){ref-type="supplementary-material"}. For virology assessments, bilateral intranasal swabs were obtained using mid-turbinate, adult, flocked swabs (Copan Diagnostics, Murrieta, CA) at each study visit. Samples were analyzed using RT-qPCR to measure the RSV viral load; RSV *F* gene sequencing, to detect the development of resistance; and a multiplex assay to identify respiratory viral coinfections. All nasal samples were analyzed at central laboratories; further methodological details are provided in the [Supplementary Methods](#sup1){ref-type="supplementary-material"}. Chest X-rays or computed tomography scans were performed per standard care in patients with suspected lower respiratory tract complications (LRTC). Imaging studies and results of local microbiology tests were collected for review by the endpoint adjudication committee.

Clinical safety assessments included vital signs, body weight, and oxygen saturation by pulse oximetry; laboratory safety assessments included complete blood cell counts and liver enzyme measurements. Cardiac safety was assessed via electrocardiograms and troponin testing (per US Food and Drug Administration cardiac monitoring requirements) on Days 1, 17, and 28. Additional safety assessments included the evaluation of adverse events (AEs) and the documentation of concomitant medications.

Outcomes {#s5}
--------

The coprimary endpoints were the time-weighted, average change in the nasal RSV viral load, measured by RT-qPCR (log~10~ copies/mL) between Day 1 and Day 9, and the proportion of patients who developed LRTCs---defined as a primary RSV LRTI, a secondary bacterial LRTI, a lower respiratory tract infection due to unusual pathogens, or an LRTC of unknown etiology---from Day 1 through Day 28. The development of an LRTC was determined by an independent, blinded endpoint adjudication committee (details are in the [Supplementary Methods](#sup1){ref-type="supplementary-material"}). The secondary efficacy endpoint was the proportion of patients who died or developed respiratory failure requiring invasive mechanical ventilation from Day 1 to Day 28. Safety was assessed from AEs, vital signs, electrocardiograms, and clinical laboratory test results.

Statistical Analysis {#s6}
--------------------

Assuming a time-weighted average change in the RSV viral load from Day 1 to Day 9 of −1 log~10~ copies/mL with a standard deviation (SD) of 2 log~10~ and an LRTC event rate of 30% in patients receiving the placebo, 100 patients per treatment group were planned to provide \>80% power to detect a ≥1-log~10~ decrease in the first coprimary endpoint with a 2-sided α of 0.01 and \>90% power to detect a ≥20% reduction in the second coprimary endpoint with a 2-sided α of 0.04 in patients receiving presatovir, relative to the placebo.

The efficacy population included patients who received ≥1 dose of presatovir with a quantifiable nasal RSV viral load on Day 1. The coprimary and secondary endpoints were analyzed in the efficacy population and in prespecified subgroups defined by the randomization stratification factors (lymphopenia and ribavirin use on Day 1), and were also analyzed post hoc in subgroups defined by the duration of RSV symptoms, hospitalization status, time after HCT, and graft-vs-host disease (GVHD) status on Day 1. The safety population included patients who received ≥1 dose of presatovir.

The first coprimary analysis was performed by a parametric analysis of covariance with the baseline viral load and randomization stratification factors as covariates. The second coprimary analysis and secondary efficacy analysis were performed using 2-sided Cochran-Mantel-Haenszel tests stratified by lymphopenia (\<200 cells/mm^3^) and the intent to use ribavirin at baseline. If the number of events was small, the Fisher exact method was applied. A fallback approach was employed to control the Type I error rate at 0.05 across the coprimary and secondary endpoints (details are in the [Supplementary Methods](#sup1){ref-type="supplementary-material"}). Subgroup analyses were performed using the corresponding analysis of covariance model for the first coprimary endpoint and the Fisher exact test, with a 95% confidence interval (CI) based on the Clopper-Pearson method, for the second coprimary and secondary endpoints.

RESULTS {#s7}
=======

Patients {#s8}
--------

From 23 January 2015 to 16 June 2017, 213 patients were screened for eligibility; 24 patients were excluded, the majority (n = 14) of whom did not have a documented RSV infection of the upper respiratory tract. A total of 189 patients were randomly assigned to a study treatment (96 to presatovir and 93 to the placebo), and 185 received ≥1 dose of a study drug (95 received presatovir and 90 received the placebo; [Figure 1](#F1){ref-type="fig"}). The sponsor halted the study on 20 September 2017, before achieving the planned 200-subject enrollment, because an unplanned interim analysis before a database lock by an unblinded team indicated that results were unlikely to differ if enrollment was extended through another RSV season. Important protocol deviations are described in the [Supplementary Results and Supplementary Table 2](#sup1){ref-type="supplementary-material"}. Overall, 168 (90.8%) patients (88 assigned to presatovir and 80 to the placebo) completed treatment with a study drug through Day 17 ([Figure 1](#F1){ref-type="fig"}).

![Patient disposition from enrollment through analysis. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; RSV, respiratory syncytial virus; URT, upper respiratory tract.](ciz1166f0001){#F1}

Patient demographic and baseline clinical characteristics were generally well balanced between treatment groups, except for hospitalization of a larger number of patients receiving presatovir, compared with the placebo, at the beginning of study treatment (43.2% vs 26.7%, respectively; [Table 1](#T1){ref-type="table"}). The majority of treated patients (146/185, 78.9%) underwent allogeneic HCT, and 69/185 (37.3%) had GVHD at baseline. Lymphopenia was noted in 29 (15.7%) patients, and 44 (23.8%) patients were treated with aerosolized or oral ribavirin at baseline ([Table 1](#T1){ref-type="table"}).

###### 

Baseline Characteristics and Demographics: Safety Population

                                                                       Patients Given Presatovir, n = 95   Patients Given Placebo, n = 90   Total, N = 185
  -------------------------------------------------------------------- ----------------------------------- -------------------------------- -------------------
  Age, years, median (min, max)                                        54 (22, 70)                         53 (20, 75)                      54 (20, 75)
  Male sex at birth                                                    55 (57.9)                           55 (61.1)                        110 (59.5)
  Ethnic origin                                                                                                                             
   White                                                               66 (69.5)                           70 (77.8)                        136 (73.5)
   Asian                                                               13 (13.7)                           9 (10.0)                         22 (11.9)
   African American or African                                         6 (6.3)                             3 (3.3)                          9 (4.9)
   Other                                                               2 (2.1)                             0                                2 (1.1)
   Not documented                                                      8 (8.4)                             8 (8.9)                          16 (8.6)
  Hispanic or Latino                                                   8 (8.4)                             6 (6.7)                          14 (7.6)
  Body mass index, kg/m^2^, median (min, max)^a^                       25.0 (13.6, 49.8)                   24.3 (16.8, 46.0)                24.6 (13.6, 49.8)
  Lymphopenia, \<200 cells/µL, at randomization                        15 (15.8)                           14 (15.6)                        29 (15.7)
  Ribavirin use at randomization                                       25 (26.3)                           19 (21.1)                        44 (23.8)
   Route of administration^b^                                                                                                               
    Aerosolized                                                        4/25 (16.0)                         5/19 (26.3)                      9/44 (20.5)
    Oral                                                               21/25 (84.0)                        14/19 (73.7)                     35/44 (79.5)
  RSV type                                                                                                                                  
   RSV A                                                               44 (46.3)                           43 (47.8)                        87 (47.0)
   RSV B                                                               44 (46.3)                           43 (47.8)                        87 (47.0)
   Both RSV A and RSV B                                                2 (2.1)                             1 (1.1)                          3 (1.6)
   Undetectable                                                        5 (5.3)                             1 (1.1)                          6 (3.2)
   Missing                                                             0                                   2 (2.2)                          2 (1.1)
  Nasal RSV RNA, log~10~ copies/mL,^c^ median (min, max)               7.00 (0, 8.51)                      7.10 (0, 8.94)                   7.00 (0, 8.94)
  Respiratory symptom duration before Day 1, days, median (min, max)   4 (1, 7)                            4 (1, 10)^d^                     4 (1, 10)
  Oxygen saturation, %, median (min, max)                              96 (87, 100)                        96 (90, 100)                     96 (87, 100)
  Smoking history                                                                                                                           
   Never                                                               52 (54.7)                           52 (57.8)                        104 (56.2)
   Former                                                              40 (42.1)                           35 (38.9)                        75 (40.5)
   Current                                                             3 (3.2)                             3 (3.3)                          6 (3.2)
  Other respiratory viruses detected                                                                                                        
   Rhinovirus or enterovirus                                           2 (2.1)                             3 (3.3)                          5 (2.7)
   Adenovirus                                                          1 (1.1)                             1 (1.1)                          2 (1.1)
   Coronavirus 229E                                                    0                                   3 (3.3)                          3 (1.6)
   Coronavirus HKU1                                                    1 (1.1)                             1 (1.1)                          2 (1.1)
   Coronavirus NL63                                                    0                                   1 (1.1)                          1 (0.5)
   Coronavirus OC43                                                    1 (1.1)                             0                                1 (0.5)
   Parainfluenza 1                                                     1 (1.1)                             0                                1 (0.5)
   Parainfluenza 2                                                     1 (1.1)                             0                                1 (0.5)
  Hospitalized on Day 1                                                41 (43.2)                           24 (26.7)                        65 (35.1)
   Unplanned hospitalization                                           27 (65.9)                           11 (45.8)                        38 (58.5)
   Planned hospitalization                                             14 (34.1)                           13 (54.2)                        27 (41.5)
   Hospitalization related to RSV infection                            24 (58.5)                           8 (33.3)                         32 (49.2)
   Hospitalization days before Day 1, median (min, max)                0 (0, 48)                           0 (0, 75)                        0 (0, 75)
  Hematopoietic-cell transplant type                                                                                                        
   Allogeneic HCT                                                      72 (75.8)                           74 (82.2)                        146 (78.9)
   Autologous HCT                                                      23 (24.2)                           16 (17.8)                        39 (21.1)
   Time from HCT to Day 1, days, median (min, max)^e^                  278 (2, 4000)                       275 (1, 7538)                    278 (1, 7538)
  Underlying hematologic disease                                                                                                            
   Acute leukemia                                                      44 (46.3)                           49 (54.4)                        93 (50.3)
   Myeloma                                                             24 (25.3)                           13 (14.4)                        37 (20.0)
   Lymphoma                                                            11 (11.6)                           14 (15.6)                        25 (13.5)
   Refractory anemia                                                   1 (1.1)                             0                                1 (0.5)
   Chronic lymphocytic leukemia                                        4 (4.2)                             1 (1.1)                          5 (2.7)
   Other                                                               15 (15.8)                           13 (14.4)                        28 (15.1)
  Acute or chronic graft-vs-host disease                                                                                                    
   Yes                                                                 33 (34.7)                           36 (40.0)                        69 (37.3)
   No                                                                  37 (38.9)                           37 (41.1)                        74 (40.0)
   Not applicable, autologous HCT                                      23 (24.2)                           16 (17.8)                        39 (21.1)
   Unknown                                                             2 (2.1)                             1 (1.1)                          3 (1.6)
  HCT donor type                                                                                                                            
   Unrelated                                                           44 (46.3)                           35 (38.9)                        79 (42.7)
   Matched-related                                                     24 (25.3)                           32 (35.6)                        56 (30.3)
   Mismatched-related                                                  3 (3.2)                             6 (6.7)                          9 (4.9)
   Autologous                                                          23 (24.2)                           17 (18.9)                        40 (21.6)
   Unknown                                                             1 (1.1)                             0                                1 (0.5)
  Stem-cell source                                                                                                                          
   Peripheral blood                                                    72 (75.8)                           75 (83.3)                        147 (79.5)
   Bone marrow                                                         11 (11.6)                           8 (8.9)                          19 (10.3)
   Cord blood                                                          7 (7.4)                             5 (5.6)                          12 (6.5)
   Other                                                               2 (2.1)                             1 (1.1)                          3 (1.6)
   Unknown                                                             3 (3.2)                             1 (1.1)                          4 (2.2)
  Recipient CMV seropositive                                           57 (60.0)                           60 (66.7)                        117 (63.2)

Data are presented as n (%) unless otherwise noted.

Abbreviations: CMV, cytomegalovirus; HCT, hematopoietic cell transplant; RSV, respiratory syncytial virus.

^a^For this value, n = 94 for presatovir and n = 184 total.

^b^For this value, n = 10 for presatovir, n = 11 for placebo, and n = 21 total.

^c^For this value, n = 88 for placebo and n = 183 total.

^d^Protocol deviation related to onset of respiratory symptoms was recorded for 1 placebo-treated patient.

^e^For this value, n = 94 for presatovir and n = 184 total.

Efficacy {#s9}
--------

[Figure 2A--B](#F2){ref-type="fig"} shows the absolute RSV viral load and change from baseline at each study visit. Despite adequate plasma concentrations ([Supplementary Results; Supplementary Table 3](#sup1){ref-type="supplementary-material"}), presatovir did not significantly (prespecified α = 0.01) reduce the time-weighted average change in the RSV viral load from Day 1 to Day 9, compared with the placebo (mean, −1.26 \[SD, 0.964\] log~10~ copies/mL vs −0.91 \[SD, 1.145\] log~10~ copies/mL, respectively; treatment difference, −0.33 log~10~ copies/mL; 95% CI, −.64 to −.02 log~10~ copies/mL; *P* = .040). The development of LRTCs through Day 28 is shown in [Figure 3](#F3){ref-type="fig"}. Compared with the placebo, presatovir did not significantly reduce the proportion of patients in the efficacy population who developed an LRTC from Day 1 through Day 28 (10/89 \[11.2%\] on presatovir vs 17/87 \[19.5%\] on placebo; *P* = .11; α = 0.04). The majority of LRTC events were adjudicated as having an unknown etiology (presatovir, 7/10 \[70%\]; placebo, 15/17 \[88%\]). There were 2 events in each treatment arm that were attributed to a primary RSV LRTI, and 1 event in the presatovir arm was adjudicated as a secondary bacterial infection. Sensitivity analyses are reported in the [Supplementary Results](#sup1){ref-type="supplementary-material"}. Death or respiratory failure requiring mechanical ventilation through Day 28 occurred in 5/89 (5.6%) patients receiving presatovir and 5/87 (5.7%) patients receiving the placebo (*P* = .98; [Figure 4](#F4){ref-type="fig"}).

![Nasal respiratory syncytial virus (RSV) RNA at each study visit in the efficacy population. *A*, The median nasal RSV RNA. *B*, The median change from baseline in nasal RSV RNA at each study visit in patients treated with presatovir (closed circles, solid line) versus placebo (open circles, dashed line). Error bars represent the interquartile range.](ciz1166f0002){#F2}

![Development of lower respiratory tract complications (LRTC) in the efficacy population. The LRTC rate at each study visit in patients treated with presatovir (solid line) versus placebo (dashed line) is shown.](ciz1166f0003){#F3}

![Occurrence of death or respiratory failure requiring mechanical ventilation in the efficacy population. The event rate at each study visit in patients receiving presatovir (solid line) versus placebo (dashed line) is shown.](ciz1166f0004){#F4}

In prespecified subgroup analyses, presatovir numerically decreased the proportion of patients who developed an LRTC from Day 1 through Day 28, relative to the placebo, among patients with baseline lymphopenia (2/15 \[13.3%\] vs 9/14 \[64.3%\], respectively; *P* = .008) and those not receiving ribavirin (4/64 \[6.3%\] vs \[12/68\] 17.6%, respectively; *P* = .061; [Table 2](#T2){ref-type="table"}; [Supplementary Tables 4 and 5](#sup1){ref-type="supplementary-material"}). The proportions of patients receiving presatovir who developed LRTC were similar among patients without baseline lymphopenia and in patients without ribavirin use at baseline, as compared to those receiving the placebo ([Supplementary Tables 4 and 5](#sup1){ref-type="supplementary-material"}). Overall, ribavirin use was higher among patients who developed an LRTC (37.0%) versus those who did not (23.5%). Patients hospitalized at baseline had a numerically higher rate of LRTCs, relative to those who started treatment as outpatients (18/63 \[28.6%\] vs 9/113 \[8.0%\], respectively), and the hospitalization status was imbalanced between the presatovir and placebo arms at baseline. The effects of presatovir versus placebo treatment on the time-weighted average change in the viral load from Day 1 to Day 9 and the occurrence of death or respiratory failure requiring mechanical ventilation through Day 28 were similar between patients hospitalized and not hospitalized on Day 1 ([Supplementary Table 6](#sup1){ref-type="supplementary-material"}). However, treatment with presatovir, relative to the placebo, was associated with a 28% lower LRTC event rate among patients hospitalized on Day 1 ([Table 2](#T2){ref-type="table"}; [Supplementary Table 6](#sup1){ref-type="supplementary-material"}). In other post hoc analyses, the proportion of patients who developed LRTCs was numerically lower following presatovir treatment, as compared to placebo treatment, among patients with shorter than median symptom durations (≤4 days) and ≤365 days since HCT ([Table 2](#T2){ref-type="table"}; [Supplementary Tables 6--9](#sup1){ref-type="supplementary-material"}). A post hoc multivariate Cox proportional hazard model for the time to an LRTC through Day 28 in patients receiving presatovir, adjusted for lymphopenia and ribavirin use on Day 1, enrollment site, and hospitalization status on Day 1, yielded an adjusted hazard ratio of 0.44 (95% CI, .19--.99; *P* = .091), as compared to those receiving the placebo. Optional extended RSV monitoring and serologic responses are presented in the [Supplementary Results](#sup1){ref-type="supplementary-material"}. Patients with treatment-emergent substitutions in RSV F that were associated with presatovir resistance had a numerically smaller change in the time-weighted average RSV load, but not worse clinical outcomes, relative to those with wild-type F sequences; such substitutions occurred at a significantly higher frequency in patients with, versus without, lymphopenia ([Supplementary Results; Supplementary Tables 10--11](#sup1){ref-type="supplementary-material"}).

###### 

Post Hoc Analyses

  Patients developing LRTC, n/N (%)      Presatovir    Placebo        Treatment Difference (95% CI), %   Nominal *P* Value^a^
  -------------------------------------- ------------- -------------- ---------------------------------- ----------------------
  Lymphopenia, \<200 cells/µL            2/15 (13.3)   9/14 (64.3)    −51.0 (−77.8 to −13.1)             .008
  No ribavirin use                       4/64 (6.3)    12/68 (17.6)   −11.4 (−28.1 to 5.9)               .061
  Symptom duration ≤ median, 4 days^b^   5/48 (10.4)   13/49 (26.5)   −16.1 (−35.4 to 3.4)               .066
  Hospitalized on Day 1                  7/39 (17.9)   11/24 (45.8)   −27.9 (−50.9 to −2.4)              .023
  ≤365 days after HCT                    5/50 (10.0)   12/47 (25.5)   −15.5 (−34.8 to 4.7)               .061

Data are for LRTC development through Day 28 by presence of lymphopenia, duration of symptoms, hospitalization status, and time after HCT at Day 1. Data for other efficacy endpoints and subgroups are provided in [Supplementary Tables 4--9](#sup1){ref-type="supplementary-material"}.

Abbreviations: CI, confidence interval; HCT, hematopoietic cell transplant; LRTC, lower respiratory tract complications.

^a^ *P* values were calculated using the Fisher exact test.

^b^The median duration of respiratory symptoms on Day 1 in the efficacy population was 4 days.

Safety {#s10}
------

Overall, AEs were reported in 76 (80%) of the patients receiving presatovir and 78 (86.7%) of the patients receiving the placebo, while 18 (18.9%) of the patients receiving presatovir and 23 (25.6%) of the patients receiving the placebo had serious adverse events (SAEs). The most common AEs were diarrhea (15.8%), nausea (13.7%), and pyrexia (12.6%) in the patients receiving presatovir; and diarrhea (15.6%), vomiting (13.3%), and nausea (11.1%) in the patients receiving the placebo ([Table 3](#T3){ref-type="table"}). Most Grade 3 or 4 AEs and SAEs occurred less frequently in patients receiving presatovir, except for pyrexia as an SAE in 4 (4.2%) patients and GVHD in the gastrointestinal tract as an SAE, Grade 3 pyrexia, and Grade 4 pneumonia in 2 (2.1%) patients each ([Supplementary Tables 12--13](#sup1){ref-type="supplementary-material"}). There were no imbalances in new electrocardiogram findings or troponin abnormalities between the 2 groups. Overall, 6 patients died during the study; 2 (2.1%) were treated with presatovir and 4 (4.4%) were treated with the placebo. There were 2 patients receiving presatovir who died from gastrointestinal hemorrhage and pneumonia (1 each), and 4 patients receiving the placebo died from an LRTI, pneumonia, recurrent acute myeloid leukemia, and an intracranial hemorrhage (1 each).

###### 

Adverse Events and Laboratory Abnormalities Reported in ≥4 Patients in a Treatment Group in the Safety Population

  Adverse Event             Presatovir, n = 95   Placebo, n = 90
  ------------------------- -------------------- -----------------
  Any adverse event         76 (80.0)            78 (86.7)
  Serious adverse events    18 (18.9)            23 (25.6)
  Grade ≥3 adverse events   22 (23.2)            21 (23.3)
  Diarrhea                  15 (15.8)            14 (15.6)
  Nausea                    13 (13.7)            10 (11.1)
  Vomiting                  11 (11.6)            12 (13.3)
  Pyrexia                   12 (12.6)            9 (10.0)
  Decreased appetite        7 (7.4)              6 (6.7)
  Epistaxis                 9 (9.5)              3 (3.3)
  Headache                  5 (5.3)              7 (7.8)
  Pneumonia                 4 (4.2)              7 (7.8)
  Acute kidney injury       3 (3.2)              7 (7.8)
  Asthenia                  3 (3.2)              7 (7.8)
  Cough                     6 (6.3)              4 (4.4)
  Dizziness                 7 (7.4)              3 (3.3)
  Rash                      4 (4.2)              5 (5.6)
  Fatigue                   4 (4.2)              4 (4.4)
  Neutropenia               3 (3.2)              5 (5.6)
  Abdominal pain            3 (3.2)              4 (4.4)
  Dyspnea                   3 (3.2)              4 (4.4)
  Febrile neutropenia       2 (2.1)              5 (5.6)
  Hypokalemia               4 (4.2)              3 (3.3)
  Anemia                    5 (5.3)              1 (1.1)
  Insomnia                  4 (4.2)              2 (2.2)
  Edema peripheral          2 (2.1)              4 (4.4)
  Dysgeusia                 1 (1.1)              4 (4.4)
  Fall                      1 (1.1)              4 (4.4)
  Fluid overload            4 (4.2)              1 (1.1)
  Hypertension              4 (4.2)              1 (1.1)
  Pain in extremity         4 (4.2)              1 (1.1)
  Dysuria                   4 (4.2)              0
  Sinusitis                 4 (4.2)              0

Data are shown as n (%).

DISCUSSION {#s11}
==========

This is the largest randomized, double blind, placebo-controlled clinical trial to date for the treatment of allogeneic and autologous HCT recipients with RSV URTIs. Presatovir treatment did not meet the coprimary endpoints of a greater time-weighted average change in the RSV viral load from Day 1 to 9 and the reduced development of LRTCs through Day 28, but was well tolerated, with a comparable safety profile relative to the placebo. In a post hoc analysis of patients with lymphopenia, the proportion who developed an LRTC through Day 28 was 51% lower following treatment with presatovir, as compared to the placebo; other post hoc analyses also indicated trends toward a treatment effect on LRTCs. The results suggest lessons for the design of future clinical trials of drugs for RSV or other respiratory viruses in transplant recipients or other immunocompromised patients.

Among healthy adults with established experimental RSV infections, presatovir treatment, as compared to the placebo treatment, significantly reduced the RSV load and clinical severity \[[@CIT0026]\]. The current study did not reproduce these findings, most likely because the challenge study participants received presatovir at or before symptom onset, whereas the current study patients were treated after a median of 4 days of symptoms. An exploratory analysis revealed trends toward reduced LRTC rates following presatovir treatment, versus placebo treatment, of patients with median or shorter symptom durations ([Table 2](#T2){ref-type="table"}). Future studies of anti-RSV drugs, particularly fusion inhibitors, should explore whether earlier therapy improves treatment outcomes.

Some transplant centers treat RSV infections in immunocompromised patients with oral or aerosolized ribavirin, despite lacking randomized clinical trial evidence \[[@CIT0001]\]. Ribavirin use in RSV-infected HCT recipients, especially those with URTIs, has been associated with more favorable outcomes in retrospective studies \[[@CIT0006], [@CIT0008], [@CIT0027]\]. In the current study, placebo-treated patients who received ribavirin had a higher LRTC progression rate, compared with those who did not (26% vs 18%, respectively), and all patients who developed an LRTC used ribavirin more frequently (37.0%), relative to those without progression (23.5%). As this was not a randomized, controlled study of ribavirin treatment, these observations require confirmation.

The observed rate of LRTCs was lower than the expected 30% used for the sample size calculation, and the Day 28 mortality was very low (\~3%) relative to previous retrospective studies \[[@CIT0002], [@CIT0007], [@CIT0010]\], possibly due to the recruitment of less severely ill patients who would not typically undergo RSV testing. Lymphopenia is a well-described risk factor for LRTCs in RSV-infected HCT recipients \[[@CIT0009], [@CIT0012], [@CIT0014], [@CIT0028]\], as observed in the current study (64% in placebo-treated patients with lymphopenia vs 11% in those without). Treatment with presatovir reduced the development of LRTCs in patients with lymphopenia---a surrogate marker of impaired T-cell or humoral immunity---possibly because robust immune responses masked any treatment effect by improving outcomes regardless of the treatment. Furthermore, lymphopenia could influence respiratory immunopathology, providing better evidence of presatovir's antiviral efficacy.

Perhaps the most important question is whether an all-cause LRTC rate is a clinically relevant endpoint and, if so, whether the observed trends are clinically meaningful. Respiratory failure and mortality are more clinically significant, but their rates in this study suggest that the sample size required would be prohibitive, especially for HCT recipients. The current study endpoint of LRTCs included multiple etiologies, because RSV URTIs may predispose patients to secondary infections---for example, by disrupting mucociliary function \[[@CIT0029], [@CIT0030]\]---so treatment could prevent a secondary LRTI, as well as a primary LRTI. Furthermore, any LRTC is a clinically significant event that may prolong hospitalization, necessitate intensive clinical care (including empiric antimicrobial treatment), and potentially result in death. Only a minority of LRTCs in this study were adjudicated as primary RSV LRTIs---likely due to other etiologies, as well as a lack of lower respiratory tract samples for the confirmation of RSV---underscoring the potential importance of nonviral pulmonary events in HCT recipients with RSV infections. Determining the cause of each LRTC event in a clinical trial, while ideal, requires invasive procedures (eg, bronchoscopy or lung biopsy) that could pose significant patient risks and are not globally mandated by the current clinical standard of care. Thus, radiographic confirmation, corroborated by clinical data with central, blinded adjudication, as used here, may be the best approach to classify LRTIs. Whether the near-50% relative reduction in LRTC events is clinically meaningful, despite lacking statistical significance, is left to interpretation. The consistent trends toward a treatment effect in exploratory analyses need confirmation in future studies.

In summary, this study provided important lessons for the design of future clinical trials of drugs for RSV and other respiratory virus infections in HCT recipients. Although the coprimary endpoints were not achieved, presatovir treatment was associated with trends toward an antiviral effect and clinical benefit. Similar future trials should judiciously select suitable at-risk patients (ie, patients with lymphopenia, neutropenia, GVHD, or receiving corticosteroids) to maximize the potential benefits. Because having an LRTC increases the mortality risk, prompt diagnoses, early intervention for RSV URTIs in high-risk patients, and effective antiviral agents are imperative to improve clinical outcomes.
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